Merck & Co. is spending $9.2 billion for Cidara Therapeutics and its lead influenza antiviral that was dropped by Johnson & ...

AbbVie is ending an eleven-year agreement with Alphabet’s Calico Labs, according to an internal email obtained by Stat News.

Applied Therapeutics’ lack of progress on govorestat as well as the potential costs to come have led analysts to question ...

Signed, sealed and delivered, Metsera is finally Pfizer’s. Pfizer has completed its acquisition of the obesity biotech, ...

After dropping so-so early-stage results on its dual GLP-1/GLP-2 agonist earlier this year, fierce competition in the obesity ...

Third Arc Bio is paying $5 million upfront to use Adagene’s tech in hopes of creating two new masked T-cell engagers. | Third ...

Mersana Therapeutics' decision earlier this year to go all-in on its antibody-drug conjugate Emi-Le appears to have paid ...

In a highly anticipated article, FDA officials Vinay Prasad, M.D., and Martin Makary, M.D., outlined a novel regulatory ...

After forming from a merger hashed out over plates of tacos about a year ago, nChroma Bio is laying off staff and ...

European life sciences investor Medicxi has raised 500 million euros (about $581.6 million) to go directly toward innovative ...

Bristol Myers Squibb and Johnson & Johnson have stopped a phase 3 anticoagulant trial early for futility, closing off one avenue to market for a molecule tipped to generate multibillion-dollar sales.

As part of that relocation, about 70 employees—less than 5% of the total at the site—are being laid off, the spokesperson said. Some affected staffers may be able to move to other positions within the ...